Trevarx Biomedical, Inc.
Philadelphia, PA
- UEI
- PC6KVBCJAPK9
- CAGE
- 8M8Y1
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 262 S Van Pelt St, Philadelphia, PA 19103, USA
- Website
- trevarx.com
- Founded
- 2016
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Optimizing radiosynthetic yield of [18F]FTT for wide-spread distribution | National Cancer Institute (NIH) | $2,022,982 | |
| Optimizing radiosynthetic yield of [18F]FTT for wide-spread distribution | National Cancer Institute (NIH) | $1,170,174 |
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The Trustees Of The University Of Pennsylvania | R01CA258717 | $53,380 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Cellsight Technologies, Inc. | San Francisco, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Theracea Pharma LC | Tucson, AZ | — |
| Collagen Medical LLC | Boston, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Senex Biotechnology Inc. | Maynard, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Biovinc, LLC | Pasadena, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Trevarx Biomedical, Inc. is a biotechnology company focused on developing small molecule radiopharmaceutical platforms for the treatment of breast, ovarian, and prostate cancer. It was registered in SAM.gov in May 2020 as a corporate entity and for-profit organization.
Trevarx Biomedical has received two federal project grants totaling over $2.2 million from the National Cancer Institute of the National Institutes of Health. The grants support development and optimization of Trevarx's radiotracer product called [18F]FluorThanatrace ([18F]FTT), which is a PET-radiolabeled analog of the PARP inhibitor drug rucaparib. [18F]FTT provides quantitative images of regional PARP expression, allowing it to serve as a companion diagnostic to identify patients most likely to respond to PARP inhibitor cancer therapy. One $1.04 million grant funds efforts to maximize production consistency and radiochemical yield of [18F]FTT to prepare for phase 3 clinical trials and regulatory approval. This includes work to establish widespread radiopharmaceutical supply, a "best practice" synthesis template combining academic and commercial efforts, and rollout of [18F]FTT production with a radiopharmaceutical supplier partner. A prior $1.17 million grant supported optimizing the [18F]FTT synthesis platform and testing simplified purification methods. The University of Pennsylvania received a sub-award on one of the grants as a partner on synthesis and purification optimization.
Quick answers
Is Trevarx Biomedical, Inc. registered in SAM.gov?
Yes. Trevarx Biomedical, Inc.'s SAM.gov registration is active through October 21, 2026.
What is Trevarx Biomedical, Inc.'s most recent federal award?
Trevarx Biomedical, Inc.'s most recent federal grant award is Optimizing radiosynthetic yield of [18F]FTT for wide-spread distribution (R42CA261259), from National Cancer Institute (NIH), on April 1, 2021.
On GovTribe
See Trevarx Biomedical, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors